Drugs / Pyrazinamid
Trials 0
Also used as a comparator or background therapy in 3 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07058090 Comparator | Jul → Dec 2025 overdue | drug-induced liver injury, tuberculosis | Liaquat National Hospital & Medical College | Not yet recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07303699 Background | Jan 2026 → Mar 2027 expected | pulmonary tuberculosis | Obafemi Awolowo University Teaching Hospital | Recruiting | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT00495326 Background | Dec 2007 → Apr 2011 | AIDS, tuberculosis | French National Agency for Research on AIDS and Viral Hepatitis | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pyrazinamid | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07058090 ↗ |
| Route | Oral | “daily oral treatment with rifampin, isoniazid, pyrazinamide, ethambutol” NCT07303699 ↗ |